Research programme: immune checkpoint antibodies - ImmuneOncia Therapeutics

Drug Profile

Research programme: immune checkpoint antibodies - ImmuneOncia Therapeutics

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Sorrento Therapeutics
  • Developer ImmuneOncia Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 May 2016 ImmuneOncia Therapeutics plans phase I trial for cancer in South Korea
  • 02 Mar 2016 Preclinical trials in Cancer in South Korea before March 2016 (Parenteral)
  • 02 Mar 2016 Yuhan and Sorrento Therapeutics agree to co-develop and co-promote immune checkpoint inhibitors in South Korea for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top